Most edibles sold in 2026 with the word "wellness" on the package are recreational products in different packaging. The lavender sprig, the soft pastel color palette, the words "calm" and "balance" set in lowercase serif. None of it changes what's inside the gummy. Ten milligrams of THC, a vague "blend" of minor cannabinoids printed in microscopic type on the back, a marketing claim about sleep or anxiety or focus that the brand's own COA can't substantiate. The packaging changed. The product didn't.
This is going to break on November 12, 2026. Section 781 of H.R. 5371 redefines hemp on a total-THC basis with a per-container cap, which kills the intoxicating hemp-derived market by federal preemption. The state-licensed cannabis market survives, but the survivors face a question they have spent a decade avoiding. If you want to keep selling products marketed as therapeutic, you are going to have to actually be therapeutic. The recreational consumer who used to tolerate "wellness" as a vibe now has fewer options and more skepticism. The medical patient who wants something defensible to bring up with a clinician has almost nothing on the shelf that meets the bar.
Someone is going to build the first edible that a doctor could recommend without flinching. The brand that gets there first owns a category that doesn't exist yet. So before any of those products launch, here is the standard. Five criteria. If a product fails any one of them, what remains is a recreational edible with better marketing.
1. A cannabinoid ratio backed by published research
Most "sleep gummies" contain THC and a sprinkle of CBN. Most "calm gummies" contain THC and a sprinkle of CBD. Most "energy gummies" contain THC and a sprinkle of CBG plus caffeine, which is the cannabinoid version of asking who put their cup down on the science.
A real medical formulation specifies a ratio. Two-to-one CBD to THC for anxiety reduction with reduced psychoactivity. One-to-one for moderate pain conditions, where the combined formulation outperforms either cannabinoid alone in published trials. CBN-dominant with low THC support for sedation, where the 2021 Journal of Cannabis Research review on CBN found preliminary evidence of sedative effect at doses above 5 mg, paired with sub-threshold THC to engage the entourage effect without significant intoxication. These are not arbitrary. They map to actual clinical literature, including the GW Pharmaceuticals trial data on Sativex (a one-to-one THC:CBD oromucosal spray approved in over 25 countries for multiple sclerosis spasticity), the Epidiolex pediatric epilepsy trials, and the growing body of work on low-dose THC for inflammatory pain.
What does not count: "blend," "proprietary formula," "calming complex." Those words are admissions that the brand either does not know what is in the product or does not want you to know.
The test is mechanical. Pick up the package. Find the cannabinoid ratio printed in numbers, on the front, in font the same size as the brand name. If the ratio is not there, or if it is hidden on the back in 6-point type, the brand is not making a medical product. They are making a recreational product with garnish.
2. Per-piece dosing low enough that a clinician would recommend it
This is the criterion the industry wants to ignore most, because solving it cuts margins.
The dose-response curve for THC is non-linear and biphasic. Low doses produce anxiolytic, analgesic, and sleep-promoting effects. High doses produce anxiety, paranoia, tachycardia, and tolerance. The crossover point varies by individual, by route, by frequency of use, and by what else is in the product. For most cannabis-naive or occasional users, that crossover sits somewhere between 2.5 and 7.5 mg of THC.
A clinician recommending an edible for anxiety, sleep onset, or chronic pain is going to start a patient at 2.5 mg. They are going to titrate up by 2.5 mg increments. They are not going to recommend a product that comes in 10 mg pieces, because the patient will either eat half (which means dosing accuracy is now whatever a stoned patient can do with a knife at 11pm) or eat the whole thing (which means starting at the top of the curve, which is exactly the wrong place).
The standard medical edible comes in 2 mg or 5 mg pieces. Maximum. Nothing about a 10 mg gummy is medical. Nothing about a 100 mg "party pack" exists in the medical conversation at all.
Most state-licensed brands are at 5 mg or 10 mg per piece because that is where the recreational consumer's dollars-per-milligram math works out. Papa & Barkley's Releaf line at 5 mg per piece is closer to the bar than most. Wyld at 2 mg THC plus 5 mg CBN per piece, in their CBN line, is one of the few products on a state-licensed shelf that meets this criterion. Almost everything else fails it.
3. A named medical advisor with a verifiable active license
Open the brand website. Click through to the "team" page. Find the medical advisor.
If there is no medical advisor, the brand is not making a medical product. Full stop.
If there is a medical advisor, find their name. Take that name to the relevant state medical board's license verification portal. Almost every state has one. New York's is at op.nysed.gov. California's is at search.dca.ca.gov. The license either comes back active and unrestricted, or it does not.
What you will find, if you do this exercise across the dozen or so brands currently using "wellness" or "medical" or "doctor-formulated" language: a startling number of those advisors are inactive, retired, foreign-licensed, or in some cases people whose license records have disciplinary actions on them that the brand's PR team would prefer you didn't see. A few have no license at all and are referred to on the website as "Dr." because they hold a PhD in something unrelated.
A medical edible has a real advisor. Real meaning a US-licensed MD or DO with an active and unrestricted license, ideally with documented clinical experience in the condition the product targets. A pain specialist for pain products. A sleep specialist or psychiatrist for sleep products. An oncologist or palliative care physician for products positioned around chemotherapy support. The license number is published. The CV is public. The advisor is named on the package, not buried on a subpage.
Anything less is theater.
4. A published per-batch certificate of analysis, accessible without friction
The COA is the only document in the entire cannabinoid industry that approaches a medical-grade evidence standard. It is the lab report. It tells you what is actually in the product, batch by batch, including potency, terpene profile, residual solvents, pesticides, heavy metals, mycotoxins, and microbial contamination.
Every state-licensed brand technically has a COA on every batch. Producing one is required to legally sell the product. The question is whether the patient can find it.
The standard medical edible publishes the COA on the brand website, indexed by batch number, accessible without a login or a form submission, and the batch number on the package matches a COA that is no more than 60 days old at point of sale. The patient should be able to take the package, pull out a phone, and have the COA on screen in under thirty seconds.
What you find on most brand websites: a "lab results" page that links to a generic certificate from a year ago, or a contact form that says "request batch information by emailing customer service," or nothing at all. Some brands publish a single representative COA and have not updated it in eighteen months. None of this counts. If the patient cannot match the package in their hand to a current lab report on the brand's site without help, the brand is not transparent enough to be making a medical product.
There is one further bar. The COA needs to come from an ISO/IEC 17025-accredited lab, and the brand's name needs to appear on the lab's report as the customer of record. Self-published "in-house COAs" that are not from an independent accredited lab are marketing documents, not medical documents.
5. State-licensed distribution only, no hemp-derived shortcut
Until November 12, 2026, the hemp-derived shortcut is open. Brands have spent the last several years exploiting Section 10113 of the 2018 Farm Bill to send intoxicating products through gas stations, vape shops, and direct-to-consumer mail order, claiming hemp-derived status because the delta-9 THC content sits below 0.3% by dry weight even when the per-piece psychoactive load is identical to a state-licensed gummy.
The federal hemp ban closes that route. Total-THC standards plus per-container caps mean a hemp-derived product can no longer carry a meaningful psychoactive dose without violating the new definition.
But the question is not about regulatory survival. The question is about whether a serious medical product would have ever taken the shortcut in the first place. The answer is no. State medical cannabis programs exist precisely so that products marketed for therapeutic use are produced under tighter controls, distributed through licensed channels, and consumed by patients whose use is documented in some form. The hemp-derived channel was always designed for recreational consumers in non-legal states who wanted access without bothering with a medical card.
A medical edible is sold through state-licensed dispensaries only. Federal law does not currently require this. The hemp-derived alternative was always a workaround for recreational consumers in non-legal states, and a brand that built its distribution on that workaround was never serious about being medical.
The post-November market will sort this out involuntarily. The point is that any brand still operating in the hemp-derived channel as of late 2026 has revealed where their priorities are.
What the current market looks like against the standard
Run the five criteria across the most commonly cited "wellness" or "medical" edible brands.
Papa & Barkley Releaf. State-licensed only. COAs published, though batch indexing is inconsistent. Ratios printed on the package, including a 2:1 CBD:THC option. Per-piece dosing at 5 mg, which sits at the upper edge of the medical bar but does not exceed it. No named medical advisor. Three out of five.
Wyld CBN line. State-licensed only. COAs published. Ratios printed (2 mg THC, 5 mg CBN per piece) with backing literature for CBN sedation. Dosing meets the criterion. No named medical advisor. Three out of five, and the closest to the bar of any brand currently on shelves.
Kiva Camino. State-licensed only. COAs published. Per-piece dosing at 5 mg in some lines, higher in others. Cannabinoid ratios are vague ("Sleep" and "Calm" lines describe terpene blends but do not specify ratios in the medical sense). No named medical advisor. The line is positioned as wellness without committing to any of the criteria that would make it medical. Two out of five.
1906 Drops. State-licensed only. COAs published. Effects-based marketing with formulations like "Midnight" and "Bliss" that pair THC with botanicals (L-theanine, melatonin, 5-HTP). Per-piece dosing at 5 mg. No published cannabinoid ratio in the medical sense. No named medical advisor. The botanical additions actually move the product further from medical, not closer, because they introduce additional active compounds without published clinical data on the combination. Two out of five.
Wana. State-licensed and hemp-derived product lines simultaneously. The hemp-derived line is the immediate disqualifier. The state-licensed line publishes COAs but uses standard 5 mg and 10 mg dosing aimed at the recreational consumer. No named advisor, no published ratios meeting the criterion. One out of five.
Generic hemp-derived "wellness" gummies. Most of these come from a small number of contract manufacturers in North Carolina, Texas, and Tennessee, are sold under dozens of white-label brand names through gas stations and online retailers, are positioned as "wellness" or "recovery" or "sleep" products, and will be illegal in some form on November 13, 2026. None of them clear any of the five criteria. The hemp-derived shortcut alone disqualifies them. The category is going away.
The honest read of the market is that no brand currently scores five out of five. The closest scores are three. There is room on the shelf for a product that hits the standard cleanly, and the brand that gets there owns a category by default.
Why this matters for patients now, before November
Patients reading this are dealing with the current market. The federal hemp ban is six months out. In the meantime, the practical guidance is straightforward.
If you are using edibles for documented medical reasons, prioritize state-licensed products from brands that publish current per-batch COAs. Treat any product without a published ratio as a recreational product regardless of marketing language. Start at 2.5 mg, titrate up by 2.5 mg, and if the product does not come in pieces small enough to allow that, find one that does. The dosing guide and dosing calculator walk through the math.
Bring the COA to your clinician if your clinician is open to the conversation. The number of physicians willing to discuss cannabis use clinically has grown sharply over the last five years, and a published lab report changes the conversation from "patient is using something" to "patient is using a documented compound at a documented dose." That is the conversation that allows real titration, real interaction-checking against existing prescriptions, and real outcomes tracking. The medical-use guide covers the clinical conversation in detail.
What you should not do is take medical claims on packaging at face value. The packaging is a marketing surface. The COA is the medical document. If they conflict, the COA wins.
Where the standard goes from here
This is the rubric. Five criteria, defined precisely, applicable to any product that wants to be evaluated as medical instead of recreational. EdibleRank will use this standard going forward in every brand review and every ranking that touches the medical use case. Products will be scored against it. Brands that meet four or five criteria will be flagged. Brands that meet two or fewer will be flagged differently.
The November ban is going to do half the work by clearing the hemp-derived noise out of the conversation. The other half is on the state-licensed brands, who now have to decide whether they want to be in the wellness costume business or the medical business. Those are different businesses with different margins, different distribution, different advisors, and different consumers. A brand that wants both is going to lose to brands that pick one and execute.
The first brand to score five out of five on this rubric is going to be covered here in detail. So is the second. The argument here is narrow. The market does not need more edibles. It needs at least one edible that a clinician could recommend in good conscience, and as of May 2026, that product does not exist. When it does, you will read about it here first.